Luye Pharma completes enrollment for anxiety drug trial

Luye Pharma Group has completed patient enrollment for its Phase 3 clinical trial of Ruoxinlin in China, targeting Generalized Anxiety Disorder. The study enrolled 555 participants.

The company anticipates completing the trial and submitting the marketing authorization application for this indication in China by the end of 2025. Ruoxinlin is China's first locally developed proprietary antidepressant and has been used for treating depression since its 2022 launch.